UPDATE: Jefferies Raises PT on Abbott Laboratories on Attractive Valuation

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT ), and raised the price target from $40.00 to $42.00. In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in